140 is the total number of securities Novo Holdings A/S has owned. The longest Novo Holdings A/S has owned a single stock is 41 quarters.
Period | Weighting | Quarter | |||||||
---|---|---|---|---|---|---|---|---|---|
Ticker | Name | Longest | Shortest | Min. | Avg. | Max. | First | Latest | ↓ Count |
VTI | VANGUARD INDEX FDS | 29 | 12 | 14.17% | 39.63% | 64.67% | Q4 2009 | Q3 2022 | 41 |
INGN | INOGEN INC | 34 | 34 | 0.55% | 22.87% | 68.79% | Q1 2014 | Q2 2022 | 34 |
VGK | VANGUARD INTL EQUITY I... | 29 | 29 | 8.16% | 22.12% | 37.60% | Q4 2009 | Q4 2016 | 29 |
FOLD | AMICUS THERAPEUTICS INC | 22 | 22 | 0.80% | 1.83% | 4.05% | Q2 2018 | Q3 2023 | 22 |
AKBA | AKEBIA THERAPEUTICS INC | 15 | 6 | 0.25% | 2.43% | 4.83% | Q2 2014 | Q3 2020 | 21 |
VRNA | VERONA PHARMA PLC | 21 | 21 | 0.16% | 0.65% | 1.86% | Q2 2017 | Q2 2022 | 21 |
CRVS | CORVUS PHARMACEUTICALS... | 20 | 20 | 0.13% | 3.38% | 7.13% | Q1 2016 | Q4 2020 | 20 |
INSP | INSPIRE MED SYS INC | 20 | 20 | 0.26% | 0.75% | 1.83% | Q4 2018 | Q3 2023 | 20 |
CABO | CABLE ONE INC | 19 | 19 | 1.23% | 4.71% | 9.67% | Q1 2019 | Q3 2023 | 19 |
FLXN | FLEXION THERAPEUTICS INC | 7 | 6 | 0.44% | 2.35% | 4.72% | Q1 2014 | Q3 2021 | 19 |
SPNE | SEASPINE HLDGS CORP | 19 | 19 | 0.14% | 1.30% | 3.36% | Q1 2018 | Q3 2022 | 19 |
BPMC | BLUEPRINT MEDICINES CORP | 19 | 19 | 0.77% | 1.18% | 2.19% | Q1 2019 | Q3 2023 | 19 |
AAPL | APPLE INC | 18 | 18 | 2.80% | 5.70% | 10.28% | Q2 2019 | Q3 2023 | 18 |
AERI | AERIE PHARMACEUTICALS INC | 15 | 3 | 0.13% | 1.11% | 3.17% | Q4 2014 | Q4 2021 | 18 |
CRNX | CRINETICS PHARMACEUTIC... | 11 | 7 | 0.16% | 0.61% | 2.42% | Q3 2018 | Q3 2023 | 18 |
SILK | SILK ROAD MEDICAL INC | 18 | 18 | 0.22% | 0.57% | 1.36% | Q2 2019 | Q3 2023 | 18 |
SPRO | SPERO THERAPEUTICS INC | 18 | 18 | 0.02% | 0.35% | 0.85% | Q2 2019 | Q3 2023 | 18 |
MIRM | MIRUM PHARMACEUTICALS INC | 17 | 17 | 1.69% | 2.56% | 4.21% | Q3 2019 | Q3 2023 | 17 |
BAM | BROOKFIELD ASSET MGMT INC | 15 | 15 | 1.58% | 5.64% | 8.72% | Q4 2019 | Q2 2023 | 15 |
XLRN | ACCELERON PHARMA INC | 15 | 15 | 0.69% | 3.90% | 9.24% | Q1 2016 | Q3 2019 | 15 |
GRTX | GALERA THERAPEUTICS INC | 15 | 15 | 0.16% | 0.99% | 2.89% | Q4 2019 | Q2 2023 | 15 |
MIST | MILESTONE PHARMACEUTIC... | 14 | 14 | 0.26% | 2.05% | 10.17% | Q2 2019 | Q3 2022 | 14 |
INSM | INSMED INC | 14 | 14 | 0.61% | 1.08% | 2.50% | Q2 2020 | Q3 2023 | 14 |
BMTI | BIOMIMETIC THERAPEUTIC... | 13 | 13 | 2.28% | 9.06% | 15.77% | Q4 2009 | Q4 2012 | 13 |
MORF | MORPHIC HLDG INC | 13 | 13 | 0.60% | 4.72% | 8.21% | Q2 2019 | Q2 2022 | 13 |
MRUS | MERUS N V | 13 | 13 | 0.99% | 2.41% | 3.84% | Q2 2016 | Q2 2019 | 13 |
OPHT | OPHTHOTECH CORP | 12 | 12 | 14.79% | 24.44% | 37.06% | Q4 2013 | Q3 2016 | 12 |
WMGIZ | WRIGHT MEDICAL GROUP | 12 | 12 | 0.11% | 1.78% | 8.91% | Q1 2013 | Q4 2015 | 12 |
SPRB | SPRUCE BIOSCIENCES INC | 12 | 12 | 0.30% | 1.49% | 5.20% | Q4 2020 | Q3 2023 | 12 |
IVTY | INVUITY INC | 12 | 12 | 0.54% | 0.99% | 1.58% | Q4 2015 | Q3 2018 | 12 |
WMGIZ | WRIGHT MED GROUP N V | 12 | 12 | 0.01% | 0.65% | 0.98% | Q1 2016 | Q4 2018 | 12 |
NARI | INARI MED INC | 12 | 12 | 0.24% | 0.48% | 0.96% | Q2 2020 | Q1 2023 | 12 |
GLTO | GALECTO INC | 12 | 12 | 0.13% | 0.43% | 1.34% | Q4 2020 | Q3 2023 | 12 |
XENT | INTERSECT ENT INC | 9 | 3 | 0.00% | 0.42% | 0.63% | Q3 2014 | Q2 2021 | 12 |
KNTE | KINNATE BIOPHARMA INC | 12 | 12 | 0.08% | 0.38% | 0.59% | Q4 2020 | Q3 2023 | 12 |
EWTX | EDGEWISE THERAPEUTICS INC | 11 | 11 | 2.19% | 3.80% | 7.50% | Q1 2021 | Q3 2023 | 11 |
BABA | ALIBABA GROUP HLDG LTD | 11 | 11 | 1.64% | 2.65% | 3.38% | Q1 2021 | Q3 2023 | 11 |
GKOS | GLAUKOS CORP | 7 | 4 | 0.16% | 2.18% | 7.02% | Q2 2015 | Q2 2019 | 11 |
LVTX | LAVA THERAPEUTICS NV | 11 | 11 | 0.26% | 0.84% | 2.09% | Q1 2021 | Q3 2023 | 11 |
PHVS | PHARVARIS N V | 11 | 11 | 0.06% | 0.66% | 2.05% | Q1 2021 | Q3 2023 | 11 |
XENE | XENON PHARMACEUTICALS INC | 11 | 11 | 0.05% | 0.11% | 0.20% | Q4 2014 | Q2 2017 | 11 |
DERM | DERMIRA INC | 10 | 10 | 0.40% | 3.14% | 7.74% | Q4 2016 | Q1 2019 | 10 |
CYT | CYTEIR THERAPEUTICS INC | 10 | 10 | 0.14% | 2.24% | 7.45% | Q2 2021 | Q3 2023 | 10 |
PCVX | VAXCYTE INC | 6 | 4 | 0.34% | 1.65% | 3.26% | Q2 2020 | Q3 2023 | 10 |
RPHM | RENEO PHARMACEUTICALS INC | 10 | 10 | 0.45% | 1.11% | 1.87% | Q2 2021 | Q3 2023 | 10 |
ALNY | ALNYLAM PHARMACEUTICAL... | 10 | 10 | 0.20% | 0.90% | 1.74% | Q2 2021 | Q3 2023 | 10 |
TMCI | TREACE MED CONCEPTS INC | 10 | 10 | 0.35% | 0.57% | 0.92% | Q2 2021 | Q3 2023 | 10 |
LUNG | PULMONX CORP | 10 | 10 | 0.27% | 0.41% | 0.55% | Q4 2020 | Q1 2023 | 10 |
ZGNX | ZOGENIX INC | 10 | 10 | 0.12% | 0.32% | 0.57% | Q3 2019 | Q4 2021 | 10 |
NKTX | NKARTA INC | 9 | 9 | 0.52% | 3.20% | 7.36% | Q3 2020 | Q3 2022 | 9 |
NABRIVA THERAPEUTICS PLC | 9 | 9 | 0.97% | 1.80% | 3.10% | Q2 2017 | Q2 2019 | 9 | |
ETTX | ENTASIS THERAPEUTICS H... | 9 | 9 | 0.12% | 1.24% | 2.23% | Q3 2018 | Q3 2020 | 9 |
VERV | VERVE THERAPEUTICS INC | 9 | 9 | 0.70% | 1.21% | 2.12% | Q2 2021 | Q2 2023 | 9 |
RCKT | ROCKET PHARMACEUTICALS... | 9 | 9 | 0.43% | 0.88% | 1.52% | Q3 2021 | Q3 2023 | 9 |
PTGX | PROTAGONIST THERAPEUTI... | 9 | 9 | 0.04% | 0.68% | 1.19% | Q2 2019 | Q2 2021 | 9 |
HTGM | HTG MOLECULAR DIAGNOST... | 9 | 9 | 0.26% | 0.58% | 1.03% | Q2 2015 | Q2 2017 | 9 |
AKUS | AKOUOS INC | 9 | 9 | 0.24% | 0.39% | 0.68% | Q2 2020 | Q2 2022 | 9 |
CTLT | CATALENT INC | 5 | 3 | 3.61% | 5.65% | 8.63% | Q2 2020 | Q1 2023 | 8 |
RARX | RA PHARMACEUTICALS INC | 8 | 8 | 0.32% | 2.64% | 4.61% | Q4 2016 | Q3 2018 | 8 |
EWJ | ISHARES | 8 | 8 | 1.52% | 1.99% | 2.42% | Q4 2009 | Q3 2011 | 8 |
KIDS | ORTHOPEDIATRICS INC | 8 | 8 | 0.88% | 1.89% | 4.28% | Q4 2017 | Q3 2019 | 8 |
SIBN | SI BONE INC | 8 | 8 | 0.78% | 1.78% | 2.70% | Q4 2018 | Q3 2020 | 8 |
ALGS | ALIGOS THERAPEUTICS INC | 8 | 8 | 0.10% | 1.49% | 3.10% | Q4 2020 | Q3 2022 | 8 |
VECT | VECTIVBIO HLDG AG | 8 | 8 | 0.82% | 1.32% | 2.03% | Q2 2021 | Q1 2023 | 8 |
TKAI | TOKAI PHARMACEUTICALS INC | 8 | 8 | 0.08% | 0.92% | 1.51% | Q3 2014 | Q2 2016 | 8 |
STIM | NEURONETICS INC | 8 | 8 | 0.06% | 0.78% | 1.43% | Q3 2018 | Q2 2020 | 8 |
IO BIOTECH INC | 8 | 8 | 0.41% | 0.63% | 0.99% | Q4 2021 | Q3 2023 | 8 | |
BHVN | BIOHAVEN PHARMACTL HLD... | 8 | 8 | 0.12% | 0.26% | 0.40% | Q3 2019 | Q2 2021 | 8 |
MQ | MARQETA INC | 8 | 8 | 0.13% | 0.20% | 0.36% | Q4 2021 | Q3 2023 | 8 |
ASML | ASML HOLDING N V | 7 | 7 | 4.49% | 7.82% | 11.08% | Q1 2022 | Q3 2023 | 7 |
CRM | SALESFORCE.COM, INC. | 7 | 7 | 3.35% | 5.75% | 8.66% | Q1 2022 | Q3 2023 | 7 |
CLCD | COLUCID PHARMACEUTICAL... | 7 | 7 | 1.22% | 4.57% | 10.94% | Q2 2015 | Q4 2016 | 7 |
TSM | TAIWAN SEMICONDUCTOR M... | 7 | 7 | 2.32% | 3.64% | 5.54% | Q1 2022 | Q3 2023 | 7 |
ARCELLX, INC. | 7 | 7 | 2.44% | 2.87% | 3.58% | Q1 2022 | Q3 2023 | 7 | |
BOLT | BOLT BIOTHERAPEUTICS INC | 7 | 7 | 0.26% | 2.08% | 6.12% | Q1 2021 | Q3 2022 | 7 |
NBRV | NABRIVA THERAPEUTICS AG | 7 | 7 | 0.70% | 1.19% | 2.97% | Q3 2015 | Q1 2017 | 7 |
UMRX | UNUM THERAPEUTICS INC | 7 | 7 | 0.12% | 0.92% | 3.97% | Q1 2018 | Q3 2019 | 7 |
CMPI | CHECKMATE PHARMACEUTIC... | 7 | 7 | 0.30% | 0.77% | 1.36% | Q3 2020 | Q1 2022 | 7 |
IOVA | IOVANCE BIOTHERAPEUTIC... | 7 | 7 | 0.60% | 0.76% | 1.07% | Q3 2020 | Q1 2022 | 7 |
RALLYBIO CORP | 7 | 7 | 0.16% | 0.59% | 0.96% | Q1 2022 | Q3 2023 | 7 | |
ABCL | ABCELLERA BIOLOGICS INC | 6 | 1 | 0.38% | 0.54% | 0.71% | Q2 2021 | Q3 2023 | 7 |
BSX | BOSTON SCIENTIFIC CORP | 6 | 6 | 3.26% | 6.07% | 8.09% | Q3 2021 | Q4 2022 | 6 |
RETA | REATA PHARMACEUTICALS INC | 6 | 6 | 2.24% | 5.77% | 8.12% | Q2 2016 | Q3 2017 | 6 |
CORT | CORCEPT THERAPEUTICS INC | 6 | 6 | 2.96% | 4.79% | 6.80% | Q2 2022 | Q3 2023 | 6 |
T107PS | WRIGHT MED GROUP INC | 6 | 6 | 0.92% | 2.84% | 5.14% | Q1 2013 | Q2 2014 | 6 |
SPNC | SPECTRANETICS CORP | 6 | 6 | 0.38% | 2.84% | 5.46% | Q1 2016 | Q2 2017 | 6 |
BMRN | BIOMARIN PHARMACEUTICA... | 6 | 6 | 1.28% | 2.05% | 2.68% | Q2 2022 | Q3 2023 | 6 |
PRAX | PRAXIS PRECISION MEDIC... | 6 | 6 | 0.14% | 1.73% | 5.76% | Q4 2020 | Q1 2022 | 6 |
TTPH | TETRAPHASE PHARMACEUTI... | 6 | 6 | 0.61% | 1.61% | 4.74% | Q4 2013 | Q1 2015 | 6 |
FRLN | FREELINE THERAPEUTICS ... | 6 | 6 | 0.17% | 0.82% | 1.85% | Q3 2020 | Q4 2021 | 6 |
CRSP | CRISPR THERAPEUTICS AG | 6 | 6 | 0.43% | 0.65% | 1.28% | Q4 2016 | Q1 2018 | 6 |
ALDR | ALDER BIOPHARMACEUTICA... | 5 | 5 | 3.96% | 6.64% | 7.86% | Q2 2014 | Q2 2015 | 5 |
OTIC | OTONOMY INC | 5 | 5 | 1.45% | 4.11% | 6.54% | Q3 2014 | Q3 2015 | 5 |
HRMY | HARMONY BIOSCIENCES HL... | 5 | 5 | 0.08% | 3.67% | 6.32% | Q3 2020 | Q3 2021 | 5 |
TBRA | TOBIRA THERAPEUTICS INC | 5 | 5 | 2.04% | 2.63% | 3.34% | Q2 2015 | Q2 2016 | 5 |
SGEN | SEAGEN INC. | 5 | 5 | 0.49% | 1.77% | 2.51% | Q3 2022 | Q3 2023 | 5 |
CNST | CONSTELLATION PHARMCET... | 5 | 5 | 0.35% | 0.64% | 0.85% | Q1 2020 | Q1 2021 | 5 |
AFIB | ACUTUS MED INC | 5 | 5 | 0.12% | 0.23% | 0.38% | Q3 2020 | Q3 2021 | 5 |
NVRO | NEVRO CORP | 4 | 4 | 3.00% | 6.18% | 8.95% | Q4 2014 | Q3 2015 | 4 |
DISC MEDICINE, INC. | 4 | 4 | 2.91% | 3.43% | 3.79% | Q4 2022 | Q3 2023 | 4 | |
MNLO | MENLO THERAPEUTICS INC | 4 | 4 | 0.74% | 2.36% | 6.42% | Q1 2018 | Q4 2018 | 4 |
KALV | KALVISTA PHARMACEUTICA... | 4 | 4 | 1.95% | 2.33% | 2.56% | Q4 2016 | Q3 2017 | 4 |
INZY | INOZYME PHARMA INC | 4 | 4 | 1.41% | 2.16% | 3.35% | Q3 2020 | Q2 2021 | 4 |
GLPG | GALAPAGOS NV | 4 | 4 | 0.78% | 1.34% | 1.76% | Q3 2018 | Q2 2019 | 4 |
APEN | APOLLO ENDOSURGERY INC | 4 | 4 | 0.17% | 1.27% | 1.94% | Q4 2016 | Q3 2017 | 4 |
FLEXION THERAPEUTICS INC | 4 | 4 | 0.34% | 0.59% | 1.06% | Q2 2019 | Q1 2020 | 4 | |
MINERVA SURGICAL INC | 4 | 4 | 0.24% | 0.51% | 0.82% | Q4 2021 | Q3 2022 | 4 | |
FSTX | F-STAR THERAPEUTICS INC | 4 | 4 | 0.00% | 0.01% | 0.02% | Q4 2020 | Q3 2021 | 4 |
SYK | STRYKER CORPORATION | 3 | 3 | 7.70% | 9.22% | 12.16% | Q2 2022 | Q4 2022 | 3 |
ANAB | ANAPTYSBIO INC | 3 | 3 | 5.42% | 7.69% | 8.96% | Q1 2017 | Q3 2017 | 3 |
LANZATECH GLOBAL INC | 3 | 3 | 4.05% | 5.95% | 8.35% | Q1 2023 | Q3 2023 | 3 | |
STE | STERIS PLC | 3 | 3 | 3.71% | 4.62% | 5.39% | Q2 2022 | Q4 2022 | 3 |
EAR | EARGO INC | 3 | 3 | 0.42% | 1.12% | 1.52% | Q4 2020 | Q2 2021 | 3 |
FDMT | 4D MOLECULAR THERAPEUT... | 3 | 3 | 0.79% | 1.11% | 1.40% | Q1 2023 | Q3 2023 | 3 |
PEN | PENUMBRA, INC. | 3 | 3 | 0.44% | 0.99% | 1.33% | Q3 2015 | Q1 2016 | 3 |
TETRAPHASE PHARMACEUTI... | 3 | 3 | 0.61% | 0.81% | 1.21% | Q4 2013 | Q2 2014 | 3 | |
MYOK | MYOKARDIA INC | 3 | 3 | 0.14% | 0.30% | 0.48% | Q3 2019 | Q1 2020 | 3 |
KZR | KEZAR LIFE SCIENCES INC | 3 | 3 | 0.10% | 0.29% | 0.52% | Q3 2022 | Q1 2023 | 3 |
OPK | OPKO HEALTH INC | 3 | 3 | 0.00% | 0.00% | 0.00% | Q3 2016 | Q1 2017 | 3 |
IRTC | IRHYTHM TECHNOLOGIES INC | 2 | 2 | 5.78% | 6.94% | 8.11% | Q4 2016 | Q1 2017 | 2 |
MDT | MEDTRONIC PLC | 2 | 2 | 5.10% | 5.47% | 5.85% | Q2 2020 | Q3 2020 | 2 |
OBSV | OBSEVA SA | 2 | 2 | 2.77% | 3.07% | 3.37% | Q1 2017 | Q2 2017 | 2 |
PTCT | PTC THERAPEUTICS INC | 2 | 2 | 1.71% | 2.24% | 2.78% | Q3 2013 | Q4 2013 | 2 |
ADAP | ADAPTIMMUNE THERAPEUTI... | 2 | 2 | 1.75% | 2.03% | 2.32% | Q2 2015 | Q3 2015 | 2 |
CBAY | CYMABAY THERAPEUTICS INC | 2 | 2 | 1.69% | 1.71% | 1.73% | Q2 2023 | Q3 2023 | 2 |
DICE THERAPEUTICS, INC. | 2 | 2 | 0.91% | 1.00% | 1.10% | Q4 2022 | Q1 2023 | 2 | |
INVUITY INC | 2 | 2 | 0.75% | 0.95% | 1.14% | Q2 2015 | Q3 2015 | 2 | |
BLU | BELLUS HEALTH INC. | 2 | 2 | 0.87% | 0.94% | 1.02% | Q4 2022 | Q1 2023 | 2 |
LEGN | LEGEND BIOTECH CORP | 2 | 2 | 0.30% | 0.41% | 0.51% | Q1 2021 | Q2 2021 | 2 |
C | CITIGROUP INC | 2 | 2 | 0.30% | 0.34% | 0.38% | Q3 2018 | Q4 2018 | 2 |
EXSCIENTIA PLC | 1 | 1 | 12.24% | 12.24% | 12.24% | Q4 2021 | Q4 2021 | 1 | |
BROOKFIELD CORP | 1 | 1 | 8.97% | 8.97% | 8.97% | Q3 2023 | Q3 2023 | 1 | |
ZSPH | ZS PHARMA INC | 1 | 1 | 1.94% | 1.94% | 1.94% | Q3 2014 | Q3 2014 | 1 |
BROOKFIELD ASSET MANAG... | 1 | 1 | 1.54% | 1.54% | 1.54% | Q3 2023 | Q3 2023 | 1 | |
CVAC | CUREVAC N V | 1 | 1 | 0.47% | 0.47% | 0.47% | Q3 2020 | Q3 2020 | 1 |
C | CITIGROUP INC | 1 | 1 | 0.35% | 0.35% | 0.35% | Q2 2018 | Q2 2018 | 1 |
ANNX | ANNEXON INC | 1 | 1 | 0.11% | 0.11% | 0.11% | Q3 2021 | Q3 2021 | 1 |
GRTS | GRITSTONE ONCOLOGY INC | 1 | 1 | 0.11% | 0.11% | 0.11% | Q1 2021 | Q1 2021 | 1 |
BAMR | BROOKFIELD ASSET MGMT ... | 1 | 1 | 0.05% | 0.05% | 0.05% | Q2 2021 | Q2 2021 | 1 |
GRAY | GRAYBUG VISION INC | 1 | 1 | 0.05% | 0.05% | 0.05% | Q1 2021 | Q1 2021 | 1 |
Download |
The securities at the top of the list , including VANGUARD INDEX FDS, INOGEN INC, and VANGUARD INTL EQUITY INDEX F, are the highest-conviction holdings of Novo Holdings A/S.
The conviction is calculated by counting the number of quarters a security has been reported by Novo Holdings A/S. The higher the number, the higher the conviction and longer the holding period.
This page lists all the securities that Novo Holdings A/S owns currently or has owned in the past.